Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Boston Scientific (NY:BSX)

44.47 +0.89 (+2.04%)
Streaming Delayed Price Updated: 2:42 PM EDT, Jul 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Boston Scientific

< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
News headline image
Why Intuitive Surgical’s Strong Quarter Still Spooked Investors ↗
Intuitive Surgical shares fell about 10% after Q2 2026 revenue rose 19% but guidance for da Vinci procedure growth wasn't raised, pushing ISRG below its 200-week moving average. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Boston Scientific (BSX): Buy, Sell, or Hold Post Q1 Earnings?
Shareholders of Boston Scientific would probably like to forget the past six months even happened. The stock dropped 52.5% and now trades at $42.79. This was... 
Via StockStory
News headline image
1 Large-Cap Stock with Exciting Potential and 2 We Turn Down
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m... 
Via StockStory
News headline image
1 Stock Under $50 to Keep an Eye On and 2 We Brush Off
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However... 
Via StockStory
Boston Scientific Corp (NYSE:BSX) Offers Strong Value with High Profitability and Solid Growth ↗
Via Chartmill
Boston Scientific Corp (NYSE:BSX) Meets All Caviar Cruise Quality Criteria for Long-Term Investors ↗
Via Chartmill
Boston Scientific Corp (NYSE:BSX): A Decent Value Play with Strong Fundamentals and an Attractive Valuation ↗
Via Chartmill
News headline image
Billionaire Steve Cohen Sold Amazon and Nvidia but Loaded Up on This Beaten-Down Stock ↗
Steve Cohen, head of Point72 Asset Management, dumped tech stocks and bought this unloved healthcare company. 
Via The Motley Fool
Topics Artificial Intelligence
These S&P500 stocks are moving in today's session ↗
Via Chartmill
News headline image
3 Value Stocks to Research Further
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t... 
Via StockStory
News headline image
2 Healthcare Stocks for Long-Term Investors and 1 We Brush Off
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali... 
Via StockStory
Tuesday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Here’s How Much You Would Have Made Owning Boston Scientific Stock In The Last 15 Years ↗
Boston Scientific (NYSE:BSX) has outperformed the market over the past 15 years by 1.07% on an annualized basis producing an average annual return of 13.28%. Currently, Boston Scientific has a market... 
Via Benzinga
News headline image
Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months ↗
Analysts remain relatively more upbeat, but this could prove fleeting. 
Via The Motley Fool
News headline image
3 S&P 500 Stocks with Solid Fundamentals
The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors. A select few continue to innova... 
Via StockStory
Topics Energy Stocks
News headline image
Why These Three Big Buybacks Are Sending Very Different Signals to Investors ↗
Quanta Services, Roblox, and Boston Scientific announced share buybacks totaling $6 billion, each under different market conditions and for different strategic reasons. 
Via MarketBeat
News headline image
Spotting Winners: Boston Scientific (NYSE:BSX) And Medical Devices & Supplies - Diversified Stocks In Q1
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
News headline image
Why Boston Scientific Stock Was Sliding This Week ↗
Sales of a key product line will likely be flat this quarter and next, company management said. 
Via The Motley Fool
News headline image
1 of Wall Street’s Favorite Stocks to Consider Right Now and 2 We Brush Off
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
Curious about the most active S&P500 stocks in today's session? ↗
Via Chartmill
Which S&P500 stocks have an unusual volume on Thursday? ↗
Via Chartmill
Gapping S&P500 stocks in Thursday's session ↗
Via Chartmill
News headline image
Stock Market Today, May 27: Boston Scientific Plunges After Reiterating Underwhelming Full Year Growth Guidance ↗
Investors weigh softer WATCHMAN and urology demand against a still-active device pipeline and capital deployment moves, today, May 27, 2026. 
Via The Motley Fool
Topics Stocks
Which S&P500 stocks are moving on Wednesday? ↗
Via Chartmill
News headline image
Boston Scientific Is Betting $1.5 Billion on a Massive Market -- and Wall Street Is Paying Attention ↗
The medical device giant just opened its wallet for a stake in a privately held company with a groundbreaking product. 
Via The Motley Fool
These S&P500 stocks are the most active in today's session ↗
Via Chartmill
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
Gapping S&P500 stocks in Wednesday's session ↗
Via Chartmill
News headline image
Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing ↗
This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious disease. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch ↗
Biotech firm Nektar Therapeutics advances a pipeline of immunology and oncology candidates through research-driven collaborations. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.